

Learning Objectives of the 26th Annual ACOG Symposium

Overall:

- At the conclusion of this activity, participants will be able to recognize the importance of a multidisciplinary team approach to achieving the best treatment outcomes for patients with prostate cancer.

Session-specific:

Presentation/Activity	Objective(s)
Session I - GU Cancer	
Update on the systemic therapy options for metastatic prostate cancer - Dr. Sohaib Al-Asaad	At the conclusion of this activity, participants will be able to list the options for systemic therapy options for advanced/metastatic prostate cancer.
Diagnostic PSMA PET scans (Virtual) - Dr. Cynthia Menard	At the conclusion of this activity, participants will be able to apply the evidence-based principles for the use of diagnostic PSMA PET scans.
Radionuclide PSMA therapy for patients with advanced prostate cancer - Dr. Jean-Mathieu Beauregard	At the conclusion of this activity, participants will be able to apply the evidence-based principles for the use of Radionuclide PSMA therapy for patients with advanced prostate cancer.
Androgen Deprivation Therapy (ADT) for patients with advanced prostate cancer - Dr. Matt Acker	At the conclusion of this activity, participants will be able to define patient selection for the various approaches to prostate cancer treatment including androgen-deprivation therapy.
Case Based Panel - Panel Discussion of Genitourinary Cancer Cases	At the conclusion of the event participants will be able to: <ol style="list-style-type: none"> 1. Summarize the role of the multidisciplinary team in the management of Genitourinary Cancers 2. Explore practical case-based options for management of genitourinary cancers.
Session II - General Oncology Topics	
The importance of exercise in cancer prevention and treatment - Dr. Scott Grandy	At the conclusion of this activity, participants will be able to describe the importance of exercise in cancer prevention and treatment.

No Fat Shame: Where We Get it Wrong and How We Can do Better - Dr. Ali Zentner	At the conclusion of this activity, participants will be able to recognize the dangers of fat-shaming and define a patient-centered approach to weight issues
Genetics Discussion on Molecular Testing - Erin Chamberlain	At the conclusion of this activity, participants will be able to define the indications for genetic and molecular testing.
CAMO Lecture {Virtual}: Choosing Wisely updated Oncology Recommendations - Dr. Safia Karim	At the conclusion of this activity, participants will be able to define and apply the Choosing Wisely updated Oncology Recommendations.
Global Oncology - Dr. Bishal Gyawali	At the conclusion of this activity, participants will be able to recognize the priorities and opportunities in global oncology
CAGPO Affiliated Meeting-ACOG Symposium	
Potent Potions & Problematic Pairs: A GPO Primer on Clinically Significant Drug-Drug Interactions in Oncology - Glenn Myers	<ol style="list-style-type: none"> 1. Recall five (5) clinically relevant drug-drug interactions (DDIs) with anti-cancer therapy, encountered in oncology practice. 2. Summarize the mechanisms and potential risks associated with these five (5) DDIs. 3. Apply practical management strategies for these five (5) DDIs in an effort to optimize drug therapy in patients with cancer. 4. Describe novel tools available for assessing DDIs in oncology practice.
Geriatric Oncology - Dr. Elizabeth Faour	<ol style="list-style-type: none"> 1. Recognize the burden of cancer in older adults. 2. Illustrate the unique context of cancer treatment in elderly patients. 3. Explain the components of geriatric assessment, the value of geriatric oncology and the methods of implementation.
Evolving Landscape of Renal Cell Carcinoma - Dr. Sohaib Al-Asaad	<ol style="list-style-type: none"> 1. Identify emerging therapies in the setting of genitourinary malignancies. 2. Illustrate the potential etiology, diagnosis and treatment of side-effects and adverse events associated with emerging therapies and combinations.